First reported case of Moraxella lacunata bacteremia following pharyngitis in an adult with paroxysmal nocturnal hemoglobinemia receiving ravulizumab: A case report

We present a rare case of <i>Moraxella lacunata</i> bacteremia in a patient receiving ravulizumab, a complement inhibitor, for paroxysmal nocturnal hemoglobinuria (PNH). <i>M. lacunata</i> is typically regarded as a commensal organism of the upper respiratory tract, and invasive infections are exceedingly uncommon. Complement inhibition therapy, while effective in reducing hemolysis and thrombosis in PNH, predisposes patients to infections, including those by uncommon organisms. This report underscores the importance of clinical vigilance for atypical pathogens in patients receiving complement inhibitors.